Cellectar Biosciences (CLRB) Income towards Parent Company (2010 - 2026)

Cellectar Biosciences has reported Income towards Parent Company for 16 years, with the latest figure at -$5.8 million in Q4 2025.

• Quarterly Income towards Parent Company rose 95.14% year-over-year to -$5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$24.0 million (up 85.12% YoY) and the FY2025 annual result came in at -$21.7 million, up 38.37% from the prior year.
• Income towards Parent Company slipped to -$5.8 million in Q4 2025 per CLRB's latest filing, from -$5.0 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$5.0 million in Q3 2025 and troughed at -$120.2 million in Q4 2024.
• A 5-year average of -$17.7 million and a median of -$7.7 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company tumbled 1205.38% in 2022, then surged 95.14% in 2025.
• Over 5 years, Income towards Parent Company stood at -$6.2 million in 2021, then sank by 1205.38% to -$80.3 million in 2022, then soared by 82.29% to -$14.2 million in 2023, then slumped by 744.87% to -$120.2 million in 2024, then soared by 95.14% to -$5.8 million in 2025.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$5.8 million, -$5.0 million, and -$6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.